KBC Group NV Acquires 813 Shares of Xencor, Inc. (NASDAQ:XNCR)

KBC Group NV lifted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 26.0% during the 4th quarter, Holdings Channel reports. The firm owned 3,936 shares of the biopharmaceutical company’s stock after purchasing an additional 813 shares during the quarter. KBC Group NV’s holdings in Xencor were worth $90,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Xencor by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company’s stock valued at $2,621,000 after buying an additional 3,635 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Xencor in the 3rd quarter valued at about $540,000. Geode Capital Management LLC grew its stake in Xencor by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock valued at $29,273,000 after buying an additional 17,658 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares in the last quarter.

Insider Transactions at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 49,278 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $24.07, for a total value of $1,186,121.46. Following the completion of the sale, the chief executive officer now directly owns 352,615 shares in the company, valued at approximately $8,487,443.05. This trade represents a 12.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Alan Bruce Montgomery sold 1,421 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the sale, the director now owns 9,140 shares of the company’s stock, valued at $247,054.20. The trade was a 13.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,366 shares of company stock worth $1,664,908 over the last three months. 5.23% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

XNCR has been the topic of a number of analyst reports. Wells Fargo & Company began coverage on shares of Xencor in a research report on Thursday, December 12th. They set an “overweight” rating and a $37.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 price target (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $34.88.

Xencor Trading Down 1.2 %

Shares of NASDAQ XNCR opened at $17.04 on Monday. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The firm has a 50 day moving average price of $22.23 and a two-hundred day moving average price of $20.98. The stock has a market cap of $1.19 billion, a P/E ratio of -5.33 and a beta of 0.70.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.